Ruth Grebenau

Title: Ruth Grebenau: Innovator in Radionuclide-Based Radioimmunodetection

Introduction

Ruth Grebenau is a notable inventor based in West Orange, NJ (US). She has made significant contributions to the field of radionuclide-based radioimmunodetection. With a total of 2 patents to her name, her work has advanced the understanding and application of protein labeling techniques.

Latest Patents

Grebenau's latest patents include innovative methods for the thiolation of proteins. One of her patents describes a method of radiolabeling a protein with a radionuclide. This involves contacting the protein with a protected tertiary thiol-containing bifunctional chelating agent. The agent reacts with the protein at one end and complexes with a radionuclide at the other end. This process forms a protein-acetyl-t-thiol-containing conjugate. The conjugate is then deprotected and mixed with a reducing agent for the radionuclide. Subsequently, the radionuclide is added to create a mixture that reacts with pendant sulfhydryl groups on the protein-t-thiol-containing conjugate. Additionally, her patents disclose methods of radioimmunotherapy and diagnostic kits suitable for human patient administration.

Career Highlights

Ruth Grebenau is associated with Immunomedics, Inc., where she continues to contribute to groundbreaking research. Her work has been pivotal in developing techniques that enhance the efficacy of radioimmunodetection and therapy.

Collaborations

Some of her notable coworkers include Seregulam V Govindan and Gary L Griffiths. Their collaborative efforts have further enriched the research environment at Immunomedics, Inc.

Conclusion

Ruth Grebenau's innovative work in radionuclide-based radioimmunodetection exemplifies her commitment to advancing medical technology. Her contributions have the potential to significantly impact patient care and treatment methodologies.